Stockscreener 앱 받기
10.54
2.32%
-0.25
시간 외 거래:
10.54
전일 마감가:
$10.79
열려 있는:
$10.66
하루 거래량:
131.85K
Relative Volume:
0.55
시가총액:
$347.42M
수익:
$65.42M
순이익/손실:
$-32.96M
주가수익비율:
-8.2992
EPS:
-1.27
순현금흐름:
$-19.87M
1주 성능:
-1.22%
1개월 성능:
-12.31%
6개월 성능:
+70.00%
1년 성능:
-24.61%
1일 변동 폭
$10.02
$10.66
1주일 범위
$10.02
$11.51
52주 변동 폭
$5.45
$15.11
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
NPCE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.54 | 347.42M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
129.89 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
93.58 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
339.59 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
81.80 | 105.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.20 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
NeuroPace, Inc. (NASDAQ:NPCE) Short Interest Update - MarketBeat
NeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Growth in Short Interest - Defense World
NeuroPace Inc (NPCE) Trading Down 3.19% on Apr 15 - GuruFocus
NeuroPace expects minimal tariff impact, maintains guidance By Investing.com - Investing.com South Africa
NeuroPace expects minimal impact of tariffs on its operations and financial results - MSN
Neuropace Provides Update On Tariff Status - marketscreener.com
NeuroPace Reports 'Minimal impact' From Trump Tariffs - MarketScreener
NeuroPace Expects Minimal Impact from Trade Tariffs - TipRanks
NeuroPace expects minimal tariff impact, maintains guidance - Investing.com
NeuroPace Provides Update on Tariff Status - The Manila Times
US Manufacturing Shield: NeuroPace Dodges Tariff Headwinds as Peers Struggle - Stock Titan
NeuroPace stock target cut to $17 by Cantor Fitzgerald - Investing.com Australia
Contrasting DIH Holding US (NASDAQ:DHAI) & NeuroPace (NASDAQ:NPCE) - Defense World
What is Leerink Partnrs' Forecast for NeuroPace Q1 Earnings? - MarketBeat
Cantor Fitzgerald cuts NeuroPace stock target to $17 By Investing.com - Investing.com Canada
Cantor Fitzgerald cuts NeuroPace stock target to $17 - Investing.com
NeuroPace reports 82% seizure reduction in epilepsy study By Investing.com - Investing.com Australia
NeuroPace Reports Data From 3-year Post-Approval Study Of RNS System In Focal Epilepsy - Nasdaq
NeuroPace reports 82% seizure reduction in epilepsy study - Investing.com
NeuroPace announces data from long-term post-approval study of RNS System - TipRanks
NeuroPace Announces Data From a Long-Term Post-Approval - GlobeNewswire
Breakthrough: New Epilepsy Device Shows 82% Seizure Reduction, FDA Study Reveals - Stock Titan
Q1 Earnings Estimate for NeuroPace Issued By Leerink Partnrs - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Sees Large Growth in Short Interest - MarketBeat
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting - The Manila Times
Breakthrough Results: NeuroPace's Brain-Responsive Epilepsy Treatment Shows 3-Year Outcomes - Stock Titan
NeuroPace Announces Refocusing of Product Portfolio - The Manila Times
NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance - MSN
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook By Investing.com - Investing.com Canada
NeuroPace to End Stereo EEG Distribution Accord; 2025 Revenue Guidance Affirmed - MarketScreener
NeuroPace to terminate distribution relationship for Seeg products - TipRanks
NeuroPace Shifts Focus to Core RNS System - TipRanks
Neuropace Inc Maintaining 2025 Revenue Guidance - MarketScreener
NeuroPace to end SEEG product distribution, maintains 2025 revenue outlook - Investing.com
NeuroPace Strategic Pivot: Higher Margins, AI Innovation, and 20% Growth Target Ahead - Stock Titan
NeuroPace (NASDAQ:NPCE) Shares Down 4.3%Should You Sell? - MarketBeat
Where are the Opportunities in (NPCE) - news.stocktradersdaily.com
Bank of New York Mellon Corp Has $328,000 Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace (NASDAQ:NPCE) Stock Price Down 4.3% – What’s Next? - Defense World
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
NeuroPace Leadership Reveals Growth Strategy: Key Insights Coming at Needham Conference - Stock Titan
(NPCE) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Seed Treatment Market Top PlayersNeuropace, Inc., Biotronik, - openPR
Cantor Fitzgerald maintains Overweight on NeuroPace stock By Investing.com - Investing.com Australia
NeuroPace at attractive entry point, remains best idea, says Cantor Fitzgerald - TipRanks
Cantor Fitzgerald maintains Overweight on NeuroPace stock - Investing.com India
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market By Investing.com - Investing.com Australia
NeuroPace’s SWOT analysis: stock poised for growth amid expanding market - Investing.com India
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로페이스 주식 (NPCE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.79%
자본화:
|
볼륨(24시간):